Active not recruiting

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

H8A-MC-LZAZ - ClinicalTrials.gov - NCT02008357

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
How long will I be in the trial?
Your participation could last approximately 4 1/2 years and include 66 visits to the study center
Email
Active not recruiting

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4)

H8A-MC-LZAZ - ClinicalTrials.gov - NCT02008357

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (protein that forms plaques in the brains of people with Alzheimer Disease [AD]).
How long will I be in the trial?
Your participation could last approximately 4 1/2 years and include 66 visits to the study center
Email

Key Requirements

Age :

65-85

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

65-85

Sex

All

Participants must

Participant must have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)

Participant must have good vein access, such that intravenous (IV) drug delivery or multiple blood draws would be able to be obtained

Participants must NOT

Participant must not be receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine

Participant must not have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in longer than expected loss of consciousness

Participant must not have a history within the past 2 years of major depression or bipolar disorder

Participant must not have a history within the past 5 years of chronic alcohol or drug abuse/dependence

Participant must not have a known history of human immunodeficiency virus (HIV)

Trial Summary

Conditions the trial is for

At Risk For Alzheimer's

What the trial is testing?

Solanezumab (LY2062430), Placebo

Could I receive a Placebo?

yes

Enrollment Goal

1150

Trial Dates

February 2014 - December 2022

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

65-85

Sex

All

Participants must

Participant must have a study partner that is willing to participate as a source of information and has at least weekly contact with the participant (contact can be in-person, via telephone or electronic communication)

Participant must have good vein access, such that intravenous (IV) drug delivery or multiple blood draws would be able to be obtained

Participants must NOT

Participant must not be receiving a prescription acetylcholinesterase inhibitor (AChEI) and/or memantine

Participant must not have a history within the last 5 years of a serious infectious disease affecting the brain (including neurosyphilis, meningitis, or encephalitis) or head trauma resulting in longer than expected loss of consciousness

Participant must not have a history within the past 2 years of major depression or bipolar disorder

Participant must not have a history within the past 5 years of chronic alcohol or drug abuse/dependence

Participant must not have a known history of human immunodeficiency virus (HIV)

Trial Summary

Conditions the trial is for

At Risk For Alzheimer's

What the trial is testing?

Solanezumab (LY2062430), Placebo

Could I receive a Placebo?

yes

Enrollment Goal

1150

Trial Dates

February 2014 - December 2022

Trial Phase

3

Not the right fit? Sign up to receive updates on new At Risk For Alzheimer's trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy

At Risk For Alzheimer's Resources

Two African American women holding hands and smiling sitting at a table with drinks, an African American man is looking at the two women smiling

Neurodegenerative Research

Click the below button to learn more about neurodegenerative disease research and clinical trials.
A photo of an older woman looking off to the side and softly smiling.

Your Questions About Alzheimer’s Research, Answered

Considering clinical trial participation may feel overwhelming. Here are some answers to common questions about Alzheimer’s and dementia clinical trials to support you through the learning curve.
Two women hugging

Memory, Alzheimer’s Disease, and Research Studies

With the help of research study participants, we are learning about aging, memory, and potential new approaches to treating Alzheimer’s disease.
Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?